{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:16:55Z","timestamp":1772446615294,"version":"3.50.1"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T00:00:00Z","timestamp":1457654400000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Millennium Pharmaceuticals Inc."}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.critrevonc.2015.12.018","type":"journal-article","created":{"date-parts":[[2016,1,2]],"date-time":"2016-01-02T16:06:01Z","timestamp":1451750761000},"page":"228-240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Panoptic clinical review of the current and future treatment of relapsed\/refractory T-cell lymphomas: Cutaneous T-cell lymphomas"],"prefix":"10.1016","volume":"99","author":[{"given":"Pier Luigi","family":"Zinzani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijayveer","family":"Bonthapally","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Huebner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Lutes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andy","family":"Chi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Pileri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.critrevonc.2015.12.018_bib0005","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1111\/j.1365-2133.2009.09037.x","article-title":"Bexarotene therapy for mycosis fungoides and S\u00e9zary syndrome","volume":"160","author":"Abbott","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0010","unstructured":"ADCETRIS\u00ae 50 mg powder for concentrate for solution for infusion. Summary of product characteristics. Takeda Pharma A\/S, Roskilde, Denmark 2015. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002455\/WC500135055.pdf accessed (02.05.5)."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0015","unstructured":"ADCETRIS\u00ae (brentuximab vedotin) for Injection. Full prescribing information. Seattle Genetics, Inc., Bothell, WA, USA 2015. Available at: http:\/\/www.adcetris.com\/pdf\/ADCETRIS-brentuximab-vedotin-Prescribing-Information.pdf accessed (02.05.15)."},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.018_bib0020","first-page":"1","article-title":"Therapeutic advances in cutaneous T-cell lymphoma","volume":"16","author":"Akilov","year":"2011","journal-title":"Skin Ther. Lett."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0025","doi-asserted-by":"crossref","first-page":"461","DOI":"10.7326\/M15-0288","article-title":"Good publication practice for communicating company-sponsored medical research: GPP3","volume":"163","author":"Battisti","year":"2015","journal-title":"Ann. Intern. Med."},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.018_bib0030","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0035","unstructured":"BELEODAQ\u00ae (belinostat) for injection, for intravenous administratio. Full prescribing information. Revised: 7\/2014. Spectrum Pharmaceuticals, Inc., Irvine, CA, USA. Available at: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/206256lbl.pdf accessed (02.05.15)."},{"issue":"12","key":"10.1016\/j.critrevonc.2015.12.018_bib0040","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.12.018_bib0045","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.11127","article-title":"Low-dose intermittent alemtuzumab in the treatment of S\u00e9zary syndrome: clinical and immunologic findings in 14 patients","volume":"92","author":"Bernengo","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.018_bib0050","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jaad.2012.07.013","article-title":"Acitretin for the treatment of cutaneous T-cell lymphoma","volume":"68","author":"Cheeley","year":"2013","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0055","unstructured":"Campath\u00ae (alemtuzumab). Injection for intravenous use. Full prescribing information. Revised: 9\/2014. Genzyme Corporation, Cambridge, MA, USA. Available at: http:\/\/www.campath.com\/pdfs\/2014-09-Campath_US_PI.pdf accessed (02.05.15)."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0060","first-page":"45","article-title":"Targeted therapy for Hodgkin lymphoma and systemic anaplastic large cell lymphoma: focus on brentuximab vedotin","volume":"7","author":"Chen","year":"2013","journal-title":"Onco Targets Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0065","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1111\/bjh.12659","article-title":"Differences in incidence and trends of haematological malignancies in Japan and the United States","volume":"164","author":"Chihara","year":"2014","journal-title":"Br. J. Haematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2015.12.018_bib0070","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1001\/archderm.143.7.854","article-title":"Incidence of cutaneous T-cell lymphoma in the United States, 1973\u20132002","volume":"143","author":"Criscione","year":"2007","journal-title":"Arch. Dermatol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0075","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.1991.9.4.565","article-title":"Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease","volume":"9","author":"Cummings","year":"1991","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.018_bib0080","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/CCO.0000000000000113","article-title":"Phosphoinositide 3-kinase inhibitors in lymphoma","volume":"26","author":"Curran","year":"2014","journal-title":"Curr. Opin. Oncol."},{"issue":"Suppl. 2","key":"10.1016\/j.critrevonc.2015.12.018_bib0085","first-page":"37","article-title":"Pentostatin treatment of cutaneous T-cell lymphoma","volume":"14","author":"Dearden","year":"2000","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0090","unstructured":"DOXIL\u00ae (doxorubicin hydrochloride liposomal injection), for intravenous use. Full prescribing information. Revised: 01\/2015. ALZA Corporation, Bedford, OH, USA. Available at: http:\/\/www.doxil.com\/shared\/product\/doxil\/prescribing-information.pdf accessed (02.16.15)."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0095","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2015.12.018_bib0100","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdu231","article-title":"Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and S\u00e9zary syndrome)","volume":"25","author":"Dummer","year":"2014","journal-title":"Ann. Oncol."},{"issue":"33","key":"10.1016\/j.critrevonc.2015.12.018_bib0105","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1200\/JCO.2011.39.8065","article-title":"Prospective international multicenter phase II trial of intravenous pegylated liposomal doxorubicin monochemotherapy in patients with stage IIB, IVA, or IVB advanced mycosis fungoides: final results from EORTC 21012","volume":"30","author":"Dummer","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2015.12.018_bib0110","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","article-title":"Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results","volume":"19","author":"Duvic","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.018_bib0115","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma","volume":"137","author":"Duvic","year":"2001","journal-title":"Arch. Dermatol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0120","doi-asserted-by":"crossref","first-page":"222","DOI":"10.3816\/CLM.2002.n.003","article-title":"Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)","volume":"2","author":"Duvic","year":"2002","journal-title":"Clin. Lymphoma"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.018_bib0125","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3816\/CLM.2006.n.039","article-title":"Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma","volume":"7","author":"Duvic","year":"2006","journal-title":"Clin. Lymphoma Myeloma"},{"issue":"11","key":"10.1016\/j.critrevonc.2015.12.018_bib0130","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1182\/blood.V108.11.2467.2467","article-title":"Oral forodesine (Bcx-1777) is clinically active in refractory cutaneous t-cell lymphoma: results of a phase I\/II study","volume":"108","author":"Duvic","year":"2006","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.018_bib0135","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1182\/blood-2006-06-025999","article-title":"Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)","volume":"109","author":"Duvic","year":"2007","journal-title":"Blood"},{"issue":"Suppl. 15","key":"10.1016\/j.critrevonc.2015.12.018_bib0140","article-title":"Long-term treatment of CTCL with the oral PNP inhibitor, forodesine","volume":"27","author":"Duvic","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2015.12.018_bib0145","doi-asserted-by":"crossref","first-page":"412","DOI":"10.3816\/CLM.2009.n.082","article-title":"Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma","volume":"9","author":"Duvic","year":"2009","journal-title":"Clin. Lymphoma Myeloma"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.12.018_bib0150","doi-asserted-by":"crossref","first-page":"514","DOI":"10.3109\/10428194.2012.720372","article-title":"Efficacy and safety of denileukin diftitox retreatment in patients with relapsed cutaneous T-cell lymphoma","volume":"54","author":"Duvic","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0155","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.clml.2013.02.020","article-title":"Duration of response in cutaneous T-cell lymphoma patients treated with denileukin diftitox: results from 3 phase III studies","volume":"13","author":"Duvic","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.018_bib0160","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.ejca.2012.08.017","article-title":"Panobinostat activity in both bexarotene-exposed and -na\u00efve patients with refractory cutaneous T-cell lymphoma: results of a phase II trial","volume":"49","author":"Duvic","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.018_bib0165","doi-asserted-by":"crossref","first-page":"4451","DOI":"10.1182\/blood.V124.21.4451.4451","article-title":"Responses to romidepsin in patients with cutaneous T-cell lymphoma (CTCL) and prior treatment with systemic chemotherapy: subanalysis from the pivotal phase 2 study","volume":"124","author":"Duvic","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.018_bib0170","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood.V124.21.3097.3097","article-title":"A dose finding lead-in study of E7777 (diphtheria toxin fragment-interleukin-2 fusion protein) in persistent or recurrent cutaneous T-cell lymphoma (CTCL)","volume":"124","author":"Duvic","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0175","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2014.60.3787","article-title":"Results of a Phase II trial of brentuximab vedotin for CD30+ cutaneous T-cell lymphoma and lymphomatoid papulosis","author":"Duvic","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2015.12.018_bib0180","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1182\/blood-2014-09-600924","article-title":"Phase 1\/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma","volume":"125","author":"Duvic","year":"2015","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.critrevonc.2015.12.018_bib0185","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/1078-0432.CCR-07-4262","article-title":"Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma","volume":"14","author":"Ellis","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0190","unstructured":"FOLOTYN\u00ae (pralatrexate injection). Solution for intravenous injection. Full prescribing information. Revised: 5\/2012. Allos Therapeutics, Inc., Westminster, CO, USA. http:\/\/www.folotyn.com\/HCP\/downloads\/folotyn_FPI_May_2012.pdf accessed (02.05.15)."},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.018_bib0195","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2004-11-4570","article-title":"A phase-1 trial of bexarotene and denileukin diftitox in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"106","author":"Foss","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0200","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/2050-7771-2-16","article-title":"Tolerability to romidepsin in patients with relapsed\/refractory T-cell lymphoma","volume":"2","author":"Foss","year":"2014","journal-title":"Biomark Res."},{"issue":"6","key":"10.1016\/j.critrevonc.2015.12.018_bib0205","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.13222","article-title":"A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma","volume":"168","author":"Foss","year":"2015","journal-title":"Br. J. Haematol."},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2015.12.018_bib0210","first-page":"58","article-title":"Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies","volume":"27","author":"Foss","year":"2000","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0215","doi-asserted-by":"crossref","first-page":"4381","DOI":"10.1182\/blood.V122.21.4381.4381","article-title":"An update on the clinical activity of resimmune, a targeted therapy directed to CD3 receptor, in patients with cutaneous T cell lymphoma-sCTCL","volume":"122","author":"Frankel","year":"2013","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0220","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1081\/CNV-100103136","article-title":"Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy","volume":"19","author":"Gabizon","year":"2001","journal-title":"Cancer Invest."},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2015.12.018_bib0225","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1053\/j.seminoncol.2007.11.003","article-title":"Pharmacology and mechanism of action of forodesine, a T-cell targeted agent","volume":"34","author":"Gandhi","year":"2007","journal-title":"Semin. Oncol."},{"issue":"Pt. 1","key":"10.1016\/j.critrevonc.2015.12.018_bib0230","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0190-9622(97)80279-4","article-title":"Pentostatin (2'-deoxycoformycin) in the treatment of cutaneous T-cell lymphoma","volume":"36","author":"Greiner","year":"1997","journal-title":"J. Am. Acad. Dermatol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0235","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1517\/13543784.2014.876407","article-title":"Novel therapies for cutaneous T-cell lymphoma: what does the future hold?","volume":"23","author":"Guenova","year":"2014","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2015.12.018_bib0240","first-page":"52","article-title":"Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer","volume":"27","author":"Ho","year":"2000","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0245","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1182\/blood.V124.21.3050.3050","article-title":"Phase 1 study of bortezomib and romidepsin in patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma, indolent B-cell lymphoma, peripheral T-cell lymphoma, or cutaneous T-cell lymphoma: updated results","volume":"124","author":"Holkova","year":"2014","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.critrevonc.2015.12.018_bib0250","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.018_bib0255","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood.V124.21.803.803","article-title":"Duvelisib (IPI-145), a phosphoinositide-3-kinase-\u03b4,\u03b3 inhibitor, shows activity in patients with relapsed\/refractory T-cell lymphoma","volume":"124","author":"Horwitz","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.critrevonc.2015.12.018_bib0260","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1038\/bjc.2013.616","article-title":"Phase II study of gemcitabine and bexarotene (GEMBEX) in the treatment of cutaneous T-cell lymphoma","volume":"109","author":"Illidge","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0265","doi-asserted-by":"crossref","first-page":"752","DOI":"10.3109\/10428194.2012.729831","article-title":"Incidence and survival patterns of cutaneous T-cell lymphomas in the United States","volume":"54","author":"Imam","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"8","key":"10.1016\/j.critrevonc.2015.12.018_bib0270","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0275","unstructured":"ISTODAX\u00ae (romidepsin) for injection. Full prescribing information. Revised: 10\/2014. Celgene Corporation, Summit, NJ, USA. Available at: http:\/\/www.istodax.com\/pdfs\/ISTODAX_PackageInsert_11192009.pdf accessed (02.05.15)."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0280","doi-asserted-by":"crossref","first-page":"951","DOI":"10.3109\/10428194.2014.938331","article-title":"CD4+ primary cutaneous small\/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature","volume":"56","author":"James","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.12.018_bib0285","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/j.1365-2133.2009.09230.x","article-title":"Gemcitabine treatment in cutaneous T-cell lymphoma: a multicentre study of 23 cases","volume":"161","author":"Jidar","year":"2009","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0290","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/jdv.12684","article-title":"Treatment of cutaneous T-cell lymphoma with oral alitretinoin","volume":"29","author":"Kapser","year":"2015","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"15","key":"10.1016\/j.critrevonc.2015.12.018_bib0295","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1182\/blood-2011-05-351346","article-title":"EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma","volume":"118","author":"Kempf","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0300","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1600-0609.2003.00143.x","article-title":"Treatment of patients with advanced mycosis fungoides and S\u00e9zary syndrome with alemtuzumab","volume":"71","author":"Kennedy","year":"2003","journal-title":"Eur. J. Haematol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0305","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1586\/17474086.2013.814833","article-title":"Romidepsin for peripheral T-cell lymphoma","volume":"6","author":"Khot","year":"2013","journal-title":"Expert Rev. Hematol."},{"issue":"7","key":"10.1016\/j.critrevonc.2015.12.018_bib0310","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archderm.139.7.857","article-title":"Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression","volume":"139","author":"Kim","year":"2003","journal-title":"Arch. Dermatol."},{"issue":"Suppl 5s","key":"10.1016\/j.critrevonc.2015.12.018_bib0315","article-title":"Phase 3 study of anti-CCR4 monoclonal antibody mogamulizumab versus vorinostat in relapsed or refractory cutaneous T-cell lymphoma (CTCL)","volume":"32","author":"Kim","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0320","article-title":"Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and S\u00e9zary syndrome with variable CD30 expression level: a multi-institution collaborative project","author":"Kim","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.018_bib0325","doi-asserted-by":"crossref","first-page":"72","DOI":"10.2340\/00015555-1886","article-title":"Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients","volume":"95","author":"Kogge","year":"2015","journal-title":"Acta Derm. Venereol."},{"issue":"11","key":"10.1016\/j.critrevonc.2015.12.018_bib0330","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamadermatol.2013.5526","article-title":"Changing incidence trends of cutaneous T-cell lymphoma","volume":"149","author":"Korgavkar","year":"2013","journal-title":"JAMA Dermatol."},{"issue":"9","key":"10.1016\/j.critrevonc.2015.12.018_bib0335","doi-asserted-by":"crossref","first-page":"976","DOI":"10.2174\/138955707781662636","article-title":"Forodesine (BCX-1777, Immucillin H) \u2013 A new purine nucleoside analogue: mechanism of action and potential clinical application","volume":"7","author":"Korycka","year":"2007","journal-title":"Mini Rev. Med. Chem."},{"issue":"10","key":"10.1016\/j.critrevonc.2015.12.018_bib0340","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1200\/JCO.1999.17.10.3117","article-title":"Pentostatin therapy of T-cell lymphomas with cutaneous manifestations","volume":"17","author":"Kurzrock","year":"1999","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.018_bib0345","first-page":"399","article-title":"Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2","volume":"91","author":"LeMaistre","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0350","first-page":"75","article-title":"Management of cutaneous T cell lymphoma: new and emerging targets and treatment options","volume":"4","author":"Li","year":"2012","journal-title":"Cancer Manag. Res."},{"issue":"11","key":"10.1016\/j.critrevonc.2015.12.018_bib0355","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1182\/blood-2002-09-2802","article-title":"Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides\/Sezary syndrome","volume":"101","author":"Lundin","year":"2003","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.critrevonc.2015.12.018_bib0360","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1200\/JCO.1994.12.12.2588","article-title":"The role of pentostatin in the treatment of T-cell malignancies: analysis of response rate in 145 patients according to disease subtype","volume":"12","author":"Mercieca","year":"1994","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.018_bib0365","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1159\/000227554","article-title":"Pentostatin (2'-deoxycoformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group","volume":"53","author":"Monfardini","year":"1996","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0370","unstructured":"National Cancer Institute. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Multiple Myeloma. Version 2.2016. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site accessed (11.12.15)."},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.018_bib0375","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-14-0830","article-title":"Reduction of regulatory T cells by mogamulizumab, a defucosylated anti-CC chemokine receptor 4 antibody, in patients with aggressive\/refractory mycosis fungoides and S\u00e9zary syndrome","volume":"21","author":"Ni","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.critrevonc.2015.12.018_bib0380","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O\u2019Connor","year":"2011","journal-title":"J. Clin Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2015.12.018_bib0385","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1200\/JCO.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.018_bib0390","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1200\/JCO.2001.19.2.376","article-title":"Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma","volume":"19","author":"Olsen","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.critrevonc.2015.12.018_bib0395","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2006.10.2434","article-title":"Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma","volume":"25","author":"Olsen","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0400","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1396-0296.2003.01643.x","article-title":"Interferon in the treatment of cutaneous T-cell lymphoma","volume":"16","author":"Olsen","year":"2003","journal-title":"Dermatol. Ther."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0405","unstructured":"ONTAK\u00ae (denileukin diftitox) Injection for intravenous infusion. Full prescribing information. Revised: August 2011. Eisai Inc., Woodcliffe Lake, NJ, USA. Available at: http:\/\/eisaiusainc.com\/wps\/wcm\/connect\/eisai\/Home\/resources\/ffc697804fdfb662a249a2c7586bf6dd\/OntakPI.pdf accessed (07.17.15)."},{"issue":"11","key":"10.1016\/j.critrevonc.2015.12.018_bib0410","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00277-014-2121-1","article-title":"Long-term outcome of patients with advanced-stage cutaneous T cell lymphoma treated with gemcitabine","volume":"93","author":"Pellegrini","year":"2014","journal-title":"Ann. Hematol."},{"issue":"32","key":"10.1016\/j.critrevonc.2015.12.018_bib0415","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2015.12.018_bib0420","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1200\/JCO.2009.26.2386","article-title":"Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma","volume":"28","author":"Prince","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.018_bib0425","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3109\/10428194.2012.706286","article-title":"Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and S\u00e9zary syndrome","volume":"54","author":"Prince","year":"2013","journal-title":"Leuk. Lymphoma"},{"issue":"18","key":"10.1016\/j.critrevonc.2015.12.018_bib0430","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Pro","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.018_bib0435","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3324\/haematol.10879","article-title":"Pegylated liposomal doxorubicin in the treatment of primary cutaneous T-cell lymphomas","volume":"92","author":"Pulini","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.critrevonc.2015.12.018_bib0440","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1001\/archderm.144.6.727","article-title":"Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or S\u00e9zary syndrome","volume":"144","author":"Quereux","year":"2008","journal-title":"Arch. Dermatol."},{"issue":"12","key":"10.1016\/j.critrevonc.2015.12.018_bib0445","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.3109\/10428190903216770","article-title":"Alemtuzumab for relapsed and refractory erythrodermic cutaneous T-cell lymphoma: a single institution experience from the Robert H. Lurie Comprehensive Cancer Center","volume":"50","author":"Querfeld","year":"2009","journal-title":"Leuk. Lymphoma"},{"issue":"17","key":"10.1016\/j.critrevonc.2015.12.018_bib0450","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1158\/1078-0432.CCR-11-0556","article-title":"Multicenter phase II trial of temozolomide in mycosis fungoides\/sezary syndrome: correlation with O6-methylguanine-DNA methyltransferase and mismatch repair proteins","volume":"17","author":"Querfeld","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.critrevonc.2015.12.018_bib0455","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1182\/blood-2013-09-525915","article-title":"Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and S\u00e9zary syndrome","volume":"123","author":"Querfeld","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0460","unstructured":"REVLIMID\u00ae (lenalidomide) capsules, for oral use. Full prescribing information. Revised: 9\/2014. Celgene Corporation, Summit, NJ, USA. Available at: http:\/\/www.revlimid.com\/wp-content\/uploads\/2013\/11\/PI.pdf accessed (02.10.15)."},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.018_bib0465","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0190-9622(98)70403-7","article-title":"Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides","volume":"39","author":"Saleh","year":"1998","journal-title":"J. Am. Acad. Dermatol."},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.018_bib0470","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/bjd.12042","article-title":"U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma","volume":"168","author":"Scarisbrick","year":"2013","journal-title":"Br. J. Dermatol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0475","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14656566.2013.770474","article-title":"Pralatrexate: evaluation of clinical efficacy and toxicity in T-cell lymphoma","volume":"14","author":"Shimanovsky","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0480","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s002800050823","article-title":"A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice","volume":"42","author":"Sirotnak","year":"1998","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.018_bib0485","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5114\/pdia.2013.33375","article-title":"Oral retinoids and rexinoids in cutaneous T-cell lymphomas","volume":"30","author":"Soko\u0142owska-Wojdy\u0142o","year":"2013","journal-title":"Postepy Dermatol. Alergol."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0490","article-title":"Polish Lymphoma Research Group experience with bexarotene in the treatment of cutaneous T-cell lymphoma","author":"Sokolowska-Wojdylo","year":"2014","journal-title":"Am. J. Ther."},{"issue":"9","key":"10.1016\/j.critrevonc.2015.12.018_bib0495","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1002\/cncr.22596","article-title":"Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma","volume":"109","author":"Straus","year":"2007","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2015.12.018_bib0500","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1093\/annonc\/mdt480","article-title":"Final results of phase II trial of doxorubicin HCl liposome injection followed by bexarotene in advanced cutaneous T-cell lymphoma","volume":"25","author":"Straus","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0505","series-title":"World Health Organization Classification of Tumours","first-page":"299270","article-title":"Pathology and genetics of tumours of hematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.12.018_bib0510","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.clml.2012.01.011","article-title":"Pilot study of denileukin diftitox alternate dosing regimen in patients with cutaneous peripheral T-cell lymphomas","volume":"12","author":"Talpur","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0515","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clml.2014.01.010","article-title":"Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed\/refractory mycosis fungoides","volume":"14","author":"Talpur","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"9","key":"10.1016\/j.critrevonc.2015.12.018_bib0520","first-page":"1283","article-title":"Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma","volume":"90","author":"Tani","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0525","unstructured":"Targretin\u00ae 75 mg soft capsules. Summary of product characteristics. Date of renewal: 25 November 2014. Eisai Ltd., Hatfield, UK. Available at: http:\/\/www.revlimid.com\/wp-content\/uploads\/2013\/11\/PI.pdf accessed (02.05.15)."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0530","unstructured":"Targretin\u00ae(bexarotene) capsules, 75mg. Full prescribing information. Revised: 05\/13. Valeant Pharmaceuticals International inc, Bridgewater, NJ, USA. Available at: http:\/\/www.targretin.com\/pdf\/Targretin%20Capsules%20PI.pdf accessed (02.05.15)."},{"issue":"8","key":"10.1016\/j.critrevonc.2015.12.018_bib0535","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.ejca.2006.01.025","article-title":"EORTC consensus recommendations for the treatment of mycosis fungoides\/S\u00e9zary syndrome","volume":"42","author":"Trautinger","year":"2006","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2015.12.018_bib0540","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/cncr.11899","article-title":"Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series","volume":"100","author":"Tsimberidou","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2015.12.018_bib0545","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2340\/00015555-1359","article-title":"Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland","volume":"92","author":"V\u00e4kev\u00e4","year":"2012","journal-title":"Acta Derm Venereol."},{"issue":"10","key":"10.1016\/j.critrevonc.2015.12.018_bib0550","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1111\/j.1346-8138.2012.01554.x","article-title":"Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"39","author":"Wada","year":"2012","journal-title":"J. Dermatol."},{"issue":"6","key":"10.1016\/j.critrevonc.2015.12.018_bib0555","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1080\/1042819031000077124","article-title":"Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression","volume":"44","author":"Wang","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0560","doi-asserted-by":"crossref","first-page":"4379","DOI":"10.1182\/blood.V122.21.4379.4379","article-title":"Response of rare variants of cutaneous T cell lymphoma (CTCL) to treatment with bexarotene. A prospective German DeCOG trial","volume":"122","author":"Weichenthal","year":"2013","journal-title":"Blood"},{"issue":"29","key":"10.1016\/j.critrevonc.2015.12.018_bib0565","doi-asserted-by":"crossref","first-page":"4485","DOI":"10.1200\/JCO.2010.28.9066","article-title":"Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma","volume":"28","author":"Whittaker","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2015.12.018_bib0570","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1182\/blood-2004-09-3502","article-title":"WHO-EORTC classification for cutaneous lymphomas","volume":"105","author":"Willemze","year":"2005","journal-title":"Blood"},{"issue":"Suppl. 6","key":"10.1016\/j.critrevonc.2015.12.018_bib0575","doi-asserted-by":"crossref","first-page":"vi149","DOI":"10.1093\/annonc\/mdt242","article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Willemze","year":"2013","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.018_bib0580","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clml.2012.06.010","article-title":"Age, race, sex, stage, and incidence of cutaneous lymphoma","volume":"12","author":"Wilson","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"11","key":"10.1016\/j.critrevonc.2015.12.018_bib0585","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.chembiol.2013.09.017","article-title":"PI3K-\u03b4 and PI3K-\u03b3 inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models","volume":"20","author":"Winkler","year":"2013","journal-title":"Chem. Biol."},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0590","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0190-9622(00)90007-0","article-title":"Treatment of relapsing or recalcitrant cutaneous T-cell lymphoma with pegylated liposomal doxorubicin","volume":"42","author":"Wollina","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.018_bib0595","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1002\/cncr.11593","article-title":"Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma","volume":"98","author":"Wollina","year":"2003","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2015.12.018_bib0600","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00262-008-0457-x","article-title":"Preclinical studies in rats and squirrel monkeys for safety evaluation of the bivalent anti-human T cell immunotoxin, A-dmDT390-bisFv(UCHT1)","volume":"57","author":"Woo","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.critrevonc.2015.12.018_bib0605","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/01.pas.0000213267.92349.59","article-title":"Chemokine receptor expression in cutaneous T cell and NK\/T-cell lymphomas: immunohistochemical staining and in vitro chemotactic assay","volume":"30","author":"Yagi","year":"2006","journal-title":"Am. J. Surg. Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.018_bib0610","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1365-2133.2005.07039.x","article-title":"Expression of chemokines and chemokine receptors in cutaneous CD30+ lymphoproliferative disorders","volume":"154","author":"Yamaguchi","year":"2006","journal-title":"Br. J. Dermatol."},{"issue":"9","key":"10.1016\/j.critrevonc.2015.12.018_bib0615","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0620","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0190-9622(96)80062-4","article-title":"Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma: results in twenty-nine patients","volume":"34","author":"Zackheim","year":"1996","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.018_bib0625","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S0190-9622(03)01591-3","article-title":"Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients","volume":"49","author":"Zackheim","year":"2003","journal-title":"J. Am. Acad. Dermatol."},{"issue":"13","key":"10.1016\/j.critrevonc.2015.12.018_bib0630","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1200\/JCO.2000.18.13.2603","article-title":"Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients","volume":"18","author":"Zinzani","year":"2000","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.018_bib0635","first-page":"702","article-title":"Preliminary observations of a phase II study of reduced-dose alemtuzumab treatment in patients with pretreated T-cell lymphoma","volume":"90","author":"Zinzani","year":"2005","journal-title":"Haematologica"},{"issue":"27","key":"10.1016\/j.critrevonc.2015.12.018_bib0640","doi-asserted-by":"crossref","first-page":"4293","DOI":"10.1200\/JCO.2007.11.4207","article-title":"Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"25","author":"Zinzani","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0645","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1093\/annonc\/mdp508","article-title":"Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome","volume":"21","author":"Zinzani","year":"2010","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2015.12.018_bib0650","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/10428194.2011.629701","article-title":"Overview of alemtuzumab therapy for the treatment of T-cell lymphomas","volume":"53","author":"Zinzani","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2015.12.018_bib0655","unstructured":"ZOLINZA\u00ae (vorinostat) capsules. Full prescribing information. Revised: 04\/2013. Patheon, Inc., Ontario, Canada. Available at: http:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zolinza\/zolinza_pi.pdf accessed (02.05.15)."},{"issue":"4","key":"10.1016\/j.critrevonc.2015.12.018_bib0660","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1001\/archderm.136.4.504","article-title":"Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients","volume":"136","author":"van Doorn","year":"2000","journal-title":"Arch. Dermatol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815301074?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842815301074?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T04:45:27Z","timestamp":1668746727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842815301074"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":132,"alternative-id":["S1040842815301074"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.12.018","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Panoptic clinical review of the current and future treatment of relapsed\/refractory T-cell lymphomas: Cutaneous T-cell lymphomas","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2015.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 The Authors. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}